2023 was a tough 12 months for that biopharma field, with quite a few firms downsizing and restructuring their workforces to stay afloat. There are indications of Restoration, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences sector while in the latter Section of 2023 and https://sites.google.com/view/bio-sites/blog